Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very aggressive type
of cancer with multiple manifestations including skin lesions, abnormal cell counts and
central nervous system (CNS) disease
involvement.
• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence
of active / uncontrolled
central nervous system involvement • History
of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose
of study drug • Known history
of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence
of history
of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use
of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start
of study treatment and for the duration
of the study